Navigation Links
Growth hormone analog may reduce risk of fatty liver disease in HIV-infected patients
Date:7/19/2014

In a preliminary study, HIV-infected patients with excess abdominal fat who received the growth hormone-releasing hormone analog tesamorelin for 6 months experienced modest reductions in liver fat, according to a study in the July 23/30 issue of JAMA, a theme issue on HIV/AIDS. Patients infected with HIV demonstrate a high prevalence of nonalcoholic fatty liver disease, estimated at 30 percent to 40 percent. The issue is being released early to coincide with the International AIDS Conference.

In human immunodeficiency virus (HIV) infection, abdominal fat accumulation is associated with ectopic (out of place) fat accumulation in the liver. Nonalcoholic fatty liver disease (NAFLD) may progress to end-stage liver disease and liver cancer. To date, there are no approved pharmacologic strategies to reduce liver fat. Tesamorelin specifically targets abdominal fat reduction but its effects on liver fat are unknown, according to background information in the article.

Takara L. Stanley, M.D., of Massachusetts General Hospital and Harvard Medical School, Boston, and colleagues randomly assigned 50 antiretroviral-treated HIV-infected men and women with abdominal fat accumulation to receive tesamorelin (n=28), or placebo (n=22), subcutaneously daily for 6 months.

The researchers found a modest but statistically significant decrease in liver fat with tesamorelin. Hepatic lipid to water percentage (a measure of liver fat), decreased in the tesamorelin group (median, -2.0 percent) compared with placebo (median, 0.9 percent). In addition, there was a significant reduction in abdominal fat: the average change was -9.9 percent with tesamorelin vs 6.6 percent with placebo.

"The decrease in liver fat in this study suggests that strategies to reduce visceral adiposity merit further investigation in HIV-infected patients with NAFLD, a condition for which there are no approved treatments. Importantly, NAFLD is associated with visceral adiposity and other metabolic abnormalities in HIV," the authors write.

"Further studies are needed to determine the clinical importance and long-term consequences of these findings."


'/>"/>

Contact: Cassandra Aviles
cmaviles@partners.org
617-724-6433
The JAMA Network Journals
Source:Eurekalert

Related medicine news :

1. Moffitt Cancer Center researchers identify drivers of sarcoma growth and survival
2. Low oxygen levels could drive cancer growth
3. Report using private health claims data shows prices are driving health spending growth
4. Mutations impair childhood growth and development by disrupting organization of chromosome pairs
5. Disease that stunts infants growth traced to same gene that makes kids grow too fast
6. Scientists discover mechanism that promotes lung cancer growth and survival
7. Nerve growth factors elevated in pancreatic cancer model
8. Exercise Wont Affect Breast Milk, Babys Growth: Study
9. QTrade's New Facility Anticipates Dramatic Growth of Tea Industry
10. Rising Solar Engineering and Design Firm Enters 1.7 MW's in Connecticut ZREC Auction and Positions for Future Growth
11. Mahvrick Expands to Brazil, Russia, India, China to Support Existing Client Customer Growth
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... panel system. , The Tranquility privacy panel system was designed to deliver ... Tranquility panels help reduce noise and provide the visual privacy required to maintain ...
(Date:1/19/2017)... ... ... Allegheny Health Network (AHN) officials today announced a bold new step to ... services in the greater Pittsburgh region. Starting January 23, patients who call AHN by ... same afternoon. , AHN is the first healthcare provider in the ...
(Date:1/19/2017)... GA (PRWEB) , ... January 19, 2017 , ... ... offers asset protection and financial planning services to communities throughout eastern Georgia, is ... fight against heart disease. , Heart disease kills more Americans every year than ...
(Date:1/19/2017)... NJ (PRWEB) , ... January 19, 2017 , ... ... locally owned insurance agency which serves Lawrenceville, New Jersey and the surrounding area, ... , Amyotrophic lateral sclerosis (ALS), more commonly known as Lou Gehrig's disease ...
(Date:1/19/2017)... ... 19, 2017 , ... Attorney Robert “RC” Pate , founder of The ... the Triumph Over Kid Cancer foundation. Each year, 175,000 children are diagnosed with pediatric ... firsthand the effect of the critical funding gap for research into pediatric cancer research. ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 2017  Abaxis, Inc. (NasdaqGS: ABAX ), ... and consumables for the medical and veterinary markets worldwide, ... results for the third quarter fiscal year 2017, ended ... p.m. ET on Thursday, January 26, 2017.  The Company ... year 2017 after the market closes on Thursday, January ...
(Date:1/19/2017)... -- ViewRay, Inc. (Nasdaq: VRAY) announced today that the German ... Germany , has purchased a MRIdian ... Clinic Heidelberg as part of its initiative for MRI-based ... be headed by Medical Director and Professor Jürgen Debus, ... German Cancer Research Center (DKFZ), the Heidelberg Heavy Ion ...
(Date:1/19/2017)... England , January 19, 2017 ... and Otsuka in the Milner Therapeutics Consortium   ... scientists in Cambridge   ... (NYSE: PFE ) as a partner to ... the Consortium, which enables the efficient transfer of materials ...
Breaking Medicine Technology: